Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0000919574-26-007570·Adage Capital Management, L.P.
Schedule 13G ownership disclosure
Karyopharm Therapeutics Inc
Common Stock, par value $0.0001 per share · CUSIP: 48576U205
Event date: 2026-09-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Adage Capital Management, L.P.
Shares: 2,013,106.00 · Class: 8.87%
- Robert Atchinson
Shares: 2,013,106.00 · Class: 8.87%
- Phillip Gross
Shares: 2,013,106.00 · Class: 8.87%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000919574-26-007570
- Form type
- SCHEDULE 13G/A
- Filer
- Adage Capital Management, L.P.
- CIK
- CIK 1535978
- Filed
- Nov 12, 2026
- Reporting period
- Sep 30, 2026
- Description
- Schedule 13G beneficial ownership